Clinical Trials
63 trialsImmunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
National Institutes of Health Clinical Center (CC)
Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer
Inova Health Care Services
INAVO-CRC
Hoffmann-La Roche
COMUNITY
Mirror Biologics, Inc.
CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer
National Cancer Institute (NCI)
A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer
National Institutes of Health Clinical Center (CC)
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
National Institutes of Health Clinical Center (CC)
EMPIRE
Institut Bergonié
Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
Gritstone bio, Inc.
Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer
City of Hope Medical Center
Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)
Roswell Park Cancer Institute
Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study
Academic and Community Cancer Research United
Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer
Sun Yat-sen University
Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)
M.D. Anderson Cancer Center
Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency Ablation
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
XHZL
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Abscopal Effect for Metastatic Colorectal Cancer
Zhejiang Provincial People's Hospital
Bohème
Ospedale Policlinico San Martino
REFIT-MSS
Translational Research in Oncology
Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
CytoDyn, Inc.
MATILDA
Gustave Roussy, Cancer Campus, Grand Paris
Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer
Translational Genomics Research Institute
Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery
Federation Francophone de Cancerologie Digestive
Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer
Roswell Park Cancer Institute
Anti-PD-1 +/- RT for MSI-H Solid Tumors
University of Colorado, Denver
OMICC
Massachusetts General Hospital
IMMUNOX
Herlev Hospital
A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer
Gilead Sciences
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Colorectal Cancer
Fuda Cancer Hospital, Guangzhou
Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC
MedImmune LLC
AMELION
SFJ Pharmaceuticals, Inc.
IRAM
Institut de Cancérologie de la Loire
PDD
Sir Mortimer B. Davis - Jewish General Hospital
ATELIER
Duke University
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.
Hoffmann-La Roche
Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC
Fujian Cancer Hospital
A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer
Galectin Therapeutics Inc.
A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer
University of Pittsburgh
AUSCOR
Barts & The London NHS Trust
Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis
Western Regional Medical Center
A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer
University of Pittsburgh
Monoclonal Antibody Therapy and Colony- Stimulating Factor in Treating Patients With Metastatic Colorectal Cancer
George Washington University
Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases
National Institutes of Health Clinical Center (CC)
Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer
University of California, Davis
PRIMIER
University of Southern California
Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients
Symphogen A/S
Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer
Alliance for Clinical Trials in Oncology
A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin
AHS Cancer Control Alberta